A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents

Trial Profile

A Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease: 2nd Switching Antiplatelet Agents

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Prasugrel (Primary) ; Ticagrelor
  • Indications Coronary artery disease; Thrombosis
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms SWAP-2
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Dec 2013 Results published in the Journal of the American College of Cardiology.
    • 20 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top